FIELD: medicine.
SUBSTANCE: invention refers to oncology. Provided is a new method of treating malignant tumours using a combined drug FTD·TPI, significantly exerts excellent anti-tumour effects with fewer side effects, where the combined drug FTD·TPI and taxane compound are administered in combination.
EFFECT: disclosed is an anti-tumour agent containing a taxane compound and an antitumour effect enhancer.
7 cl, 2 ex, 2 tbl, 4 dwg
| Title |
Year |
Author |
Number |
| ANTITUMOUR DRUG CONTAINING ANTITUMOUR PLATINUM COMPLEX, AND ANTITUMOUR EFFECT ENHANCER |
2015 |
|
RU2678103C2 |
| ANTITUMOUR AGENT AND ANTITUMOUR EFFECT ENHANCER |
2014 |
|
RU2682161C2 |
| ANTITUMOUR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE |
2014 |
|
RU2657604C2 |
| ANTITUMOR AGENT CONTAINING IMMUNOMODULATOR AND ANTITUMOR EFFECT ENHANCER |
2017 |
|
RU2747480C2 |
| METHOD FOR PREDICTING THERAPEUTIC EFFECT FOR PATIENT WITH COLORECTAL CANCER WITH INCREASED TK1 PROTEIN EXPRESSION |
2014 |
- Sakamoto, Kazuki
- Ito, Masanobu
|
RU2677656C2 |
| COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE |
2018 |
- Abastado Jean-Pierre
- Amellal Nadia
- Bruno Alain
- Burbridge Michael Frank
- Cattan Valerie
- Leger Catherine
|
RU2778887C2 |
| LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE |
2014 |
|
RU2668125C2 |
| METHOD OF TREATING PATIENTS WITH CANCER WITH SEVERE RENAL INSUFFICIENCY |
2017 |
|
RU2727598C2 |
| ANTICANCER MEDICINE, CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR |
2006 |
- Emura Tomokhiro
- Mita Akira
|
RU2394581C2 |
| TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION |
2016 |
- Kitahashi, Tsukasa
- Mima, Shinji
- Matsumoto, Takeshi
- Sekiguchi, Takahiro
- Mori, Mikinaga
|
RU2761620C2 |
